Chunhuan Lao1, Ross Lawrenson2, Melissa Edwards3, Ian Campbell3. 1. Waikato Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand. chunhuan.lao@waikato.ac.nz. 2. Waikato Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand. 3. School of Medicine, The University of Auckland, Auckland, New Zealand.
Abstract
PURPOSE: This study aims to examine the differences in characteristics, treatment and survival between Asian and European women diagnosed with stage I-III breast cancer in New Zealand. METHODS: The studied population included European women and Asian women diagnosed with stage I-III breast cancer between June 2000 and May 2013 identified from the combined Waikato and Auckland Breast Cancer Registers. Characteristics and treatment were compared between Asian and European women. Kaplan-Meier method was used to examine the survival difference. Cox proportional hazards model was used to estimate the hazard ratio (HR) of mortality. RESULTS: The studied cohort included 8608 European and 949 Asian women. Asian women were younger, had less comorbidities and were less likely to be obese than European women. Asian women were more likely to have grade 3, larger and HER2+ breast cancers. Asian women were more likely to receive mastectomy, less likely to have reconstruction after mastectomy, less likely to have chemotherapy, less likely to be treated with trastuzumab if HER2+, and had better adherence to endocrine therapy (adjusted odds ratio: 1.54; 95% CI 1.22-1.93). Asian women had better cancer-specific survival and all-cause survival than European women. The adjusted HR of cancer-specific mortality and all-cause mortality were 0.64 (95% CI 0.49-0.82) and 0.68 (95% CI 0.55-0.84), respectively. CONCLUSIONS: Asian women are more likely to have high grade, larger and HER2+ breast cancers than European women. In spite of this, they had better breast cancer outcomes. Possible explanations include the differences in adherence to endocrine therapy, age, BMI and comorbidities.
PURPOSE: This study aims to examine the differences in characteristics, treatment and survival between Asian and European women diagnosed with stage I-III breast cancer in New Zealand. METHODS: The studied population included European women and Asian women diagnosed with stage I-III breast cancer between June 2000 and May 2013 identified from the combined Waikato and Auckland Breast Cancer Registers. Characteristics and treatment were compared between Asian and European women. Kaplan-Meier method was used to examine the survival difference. Cox proportional hazards model was used to estimate the hazard ratio (HR) of mortality. RESULTS: The studied cohort included 8608 European and 949 Asian women. Asian women were younger, had less comorbidities and were less likely to be obese than European women. Asian women were more likely to have grade 3, larger and HER2+ breast cancers. Asian women were more likely to receive mastectomy, less likely to have reconstruction after mastectomy, less likely to have chemotherapy, less likely to be treated with trastuzumab if HER2+, and had better adherence to endocrine therapy (adjusted odds ratio: 1.54; 95% CI 1.22-1.93). Asian women had better cancer-specific survival and all-cause survival than European women. The adjusted HR of cancer-specific mortality and all-cause mortality were 0.64 (95% CI 0.49-0.82) and 0.68 (95% CI 0.55-0.84), respectively. CONCLUSIONS: Asian women are more likely to have high grade, larger and HER2+ breast cancers than European women. In spite of this, they had better breast cancer outcomes. Possible explanations include the differences in adherence to endocrine therapy, age, BMI and comorbidities.
Entities:
Keywords:
Adherence to endocrine therapy; Asian women; Breast cancer; Ethnic disparity; Survival
Authors: Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Ross Lawrenson; Chunhuan Lao; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne; Mark Elwood; Diana Sarfati; Marion Kuper-Hommel Journal: N Z Med J Date: 2018-05-18
Authors: Charis Brown; Chunhuan Lao; Ross Lawrenson; Sandar Tin Tin; Michelle Schaaf; Jacquie Kidd; Anne Allan-Moetaua; Josephine Herman; Reena Raamsroop; Ian Campbell; Mark Elwood Journal: N Z Med J Date: 2017-12-15
Authors: Ross Lawrenson; Chunhuan Lao; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne; Melissa Edwards; Mark Elwood; Nina Scott; Jacquie Kidd; Diana Sarfati; Marion Kuper-Hommel Journal: Cancer Causes Control Date: 2017-10-13 Impact factor: 2.506
Authors: Sanjeewa Seneviratne; Ian Campbell; Nina Scott; Rachel Shirley; Ross Lawrenson Journal: BMC Public Health Date: 2015-01-31 Impact factor: 3.295
Authors: Aparna Gunda; Mallikarjuna S Eshwaraiah; Kiran Gangappa; Taranjot Kaur; Manjiri M Bakre Journal: Breast Cancer Res Treat Date: 2022-09-10 Impact factor: 4.624
Authors: Elizabeth Buckley; Elisabeth Elder; Sarah McGill; Zahra Shahabi Kargar; Ming Li; David Roder; David Currow Journal: Breast Cancer Res Treat Date: 2021-03-21 Impact factor: 4.872
Authors: Kirsti V Hjerkind; Anna L V Johansson; Cassia B Trewin; Hege G Russnes; Giske Ursin Journal: Breast Cancer Res Date: 2022-01-10 Impact factor: 8.408